阿德福韦酯治疗HBeAg阳性慢性乙型肝炎患者4年疗效的临床研究
[A clinical study on the efficacy of HBeAg-positive chronic hepatitis B patients treated with adefovir dipivoxil for 4 years].
作者信息
Liang Jia-Yi, Yang Xiao-An, Zhang Ka, Chen Lu-Biao, Shu Xin, Xu Qi-Huan
机构信息
Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
出版信息
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2011 Oct;25(5):384-6.
OBJECTIVE
To observe the efficacy and safety on the efficacy of HBeAg-positive chronic Hepatitis B patients treated with adefovir dipivoxil for 4 years.
METHODS
Ninety-five patients with HBeAg-positive chronic hepatitis B were treated with adefovir dipivoxil 10 mg per day orally. The patients were observed before and after treatment for their serum levels of ALT and HBV DNA, the new increasing rates of serum ALT normalization, HBV DNA clearances, HBeAg loss, HBeAg seroconversion and adverse drug events.
RESULTS
At 4 years on study, the rates of ALT normalization, HBV DNA clearances, HBeAg loss, HBeAg seroconversion and HBV DNA rebound were 89.5%, 63.2%, 47.4%, 41.1% and 8.0%, respectively. No drug related to renal function impairment was found during the treatment, eight patients had adverse drug events but all were mild.
CONCLUSION
Adefovir dipivoxil could effectively inhibit HBV replication, normalize ALT and enhance transformation from HBeAg to HBeAb for cases with naive and treated-first patients. The efficacy were increased with prolongation of the treatment period. It is safe and has a good tolerance.
目的
观察阿德福韦酯治疗HBeAg阳性慢性乙型肝炎患者4年的疗效及安全性。
方法
95例HBeAg阳性慢性乙型肝炎患者口服阿德福韦酯，每日10 mg。观察治疗前后患者血清ALT和HBV DNA水平、血清ALT复常新增加率、HBV DNA清除率、HBeAg消失率、HBeAg血清学转换率及药物不良事件。
结果
研究4年时，ALT复常率、HBV DNA清除率、HBeAg消失率、HBeAg血清学转换率及HBV DNA反弹率分别为89.5%、63.2%、47.4%、41.1%和8.0%。治疗期间未发现与肾功能损害相关的药物，8例患者出现药物不良事件，但均为轻度。
结论
阿德福韦酯可有效抑制HBV复制，使ALT复常，并促进初治及经治患者HBeAg向HBeAb转换。随着治疗时间延长疗效增加。该药安全且耐受性良好。
Zotero 插件